Asthma is a common, complex disease that affects over 300 million people worldwide^[@R1]^. In the United States, the prevalence of asthma in 2001--2003 varied between ethnic groups, ranging from 7.7% in European Americans, 12.5% in African Americans, and 3.9--14.5% in Latino Americans^[@R2]^. Estimates of heritability indicate that 35--80% of the variation in risk is attributable to genetic variation^[@R3],[@R4]^, yet attempts to identify asthma susceptibility alleles by candidate gene and positional cloning studies had relatively few successes^[@R5],[@R6]^. Most genome-wide association studies (GWAS) of asthma were conducted in relatively small samples of Europeans^[@R7]^, European Americans ^[@R8]--[@R10]^, Mexicans^[@R11]^, Puerto Ricans^[@R12]^, and African Americans and African Caribbeans^[@R13]^ and did not reveal significant associations or associations that replicated across studies. In contrast, the association at the IKZF3/ZPBP2/GSDMB/ORMDL3 locus on chromosome 17q21 (henceforth referred to as the 17q21 locus) has been consistently replicated as an asthma susceptibility locus in ethnically diverse subjects from Europe, North America, and Asia^[@R14]--[@R22]^. Recently, a large meta-analysis of GWAS in European populations, called the GABRIEL Study^[@R23]^, reported significant associations with single nucleotide polymorphisms (SNPs) at six loci, including the 17q21 locus and five other regions not identified in previous GWASs of asthma. However, it is currently unknown whether the additional associations, implicating *HLA-DQ*, *IL1RL1*/*IL18R1*, *IL33*, *SMAD3*, and *IL2RB1*, play a significant role in asthma risk in European populations only or whether the earlier studies were just underpowered to detect associations with these loci.

The combined results of the previous GWAS for asthma highlight the challenges in the search for genetic risk factors for asthma. These include the large number of statistical tests performed (with millions of polymorphisms), missing genotype information (especially for rare variants, and due to inadequately designed genotyping platforms for non-European populations), modest effect sizes for associated alleles, heterogeneity in the clinical definition of disease, and the effects of a large number of potentially important environmental exposures, all of which will reduce power to detect associations. The simplest solution for increasing power is to pool data from many studies in a meta-analysis of genome-wide data sets for asthma, as in the GABRIEL Study in Europeans^[@R23]^. The goal of the EVE Consortium, which includes GWAS datasets from nine research groups in the United States ([Table 1](#T1){ref-type="table"}), is not only to increase the power to identify SNPs, genes and pathways associated with asthma risk by combining studies, but also to provide a better understanding of the patterns of variation in asthma risk genes or variants in the three major ethnic groups in the United States and to provide a more comprehensive understanding of the differences in genetic risk patterns between European American, African American/African Caribbean, and Latino individuals. Only studies of diverse populations will allow for the discovery of both robust associations that replicate across ethnic groups and unique associations that contribute to the heterogeneity in disease prevalence across different ethnic groups. Moreover, studying populations with diverse ancestries can increase the resolution of associated regions as a result of different patterns of linkage disequilibrium (LD) between racial/ethnic groups. The results reported here are based on analyses of \>2 million SNPs in 3246 asthma cases, 3385 non-asthmatic controls, 1702 asthma case-parent trios, and 355 family-based cases and 468 family-based controls, comprising three ethnic groups: European American, African American/African Caribbean, and Latino ([Table 1](#T1){ref-type="table"}).

We performed four genome-wide investigations: one meta-analysis in each of three ethnic groups and one in the combined sample. The quantile-quantile (QQ) plots of the results (see [Supplementary Figs. 1--4 online](#SD1){ref-type="supplementary-material"}) indicate that none of the studies showed inflation in test statistics, but also revealed an abundance of small p-values, especially in the combined sample. In each of the four meta-analyses, we expected (on average) approximately two p-values to be smaller than 10^−6^ by chance alone. We observed 34 SNPs with p-values smaller than 10^−6^ in the European American, four in the African American/African Caribbean, 32 in the Latino, and 75 in the combined meta-analyses (see [Supplementary Fig. 5 online](#SD1){ref-type="supplementary-material"}). In the European Americans, 33 of the SNPs are at the 17q21 asthma locus; one additional SNP on chromosome 17 (rs9891949) is 27 Mb from the 17q21 locus. In the African Americans/African Caribbeans, two SNPs are in the *PYHIN1* gene on chromosome 1q23 and two are in the intergenic region between the *NNMT* and *C11orf71* loci on chromosome 11q23. In the Latinos, 13 SNPs are on chromosome 3q27 around the *RTP2* gene, one is on chromosome 5q33 in the *GALNT10* gene, 12 are at the chromosome 17q21 locus, and two are on chromosome 19q12 between the *CCNE1* and *C19orf2* loci. One SNP in an intron of *RTP2*, rs2017908, reached genome-wide significance in the Latino samples (p=4.4×10^−9^). The 75 SNPs with p\<10^−6^ in the combined meta-analysis occur in 15 chromosomal regions; the most significant SNP in each region with at least one p\<10^−6^ in the combined sample or in one of the ethnic groups is shown in [Table 2](#T2){ref-type="table"}, with risk allele frequencies shown in [Supplementary Table 1 online](#SD1){ref-type="supplementary-material"}. Among the 75 SNPs, those at the 17q21, *IL1RLI*, and *TSLP* loci reached genome-wide significance in the combined sample (p\<2×10^−8^). The results for all SNPs with p\<10^−6^ can be found as [Supplementary Tables 2 and 3 online](#SD1){ref-type="supplementary-material"}.

We selected one SNP from each of the 15 regions with at least one p-value \<10^−6^ for replication studies (as described in [Table 2](#T2){ref-type="table"}). The samples used for replication are described in the [Supplementary Note and Supplementary Table 4 online](#SD1){ref-type="supplementary-material"}, and the results of those studies are shown in [Table 3](#T3){ref-type="table"}. Two SNPs (rs4653433 near the *SRP9* gene on chromosome 1q and rs9891949 near the *AURK* gene on chromosome 17p) could not be assayed in the replication samples. Using a Bonferroni-corrected (for 13 tests) p-value of p\<0.0038 as the threshold for significance in the replication studies, SNPs in five regions were significantly associated with asthma in the replication samples ([Table 3](#T3){ref-type="table"}).

SNPs near the 17q21 locus and the *IL1RL1*, *TSLP*, and *IL33* genes were associated with asthma in all three ethnic groups in the replication studies, whereas the *PYHIN1* association was specific to the African American replication samples. Interestingly, the associated SNPs in *PYHIN1* occur with minor allele frequencies of 0.26--0.29 in the African American/African Caribbean controls, but they are not polymorphic in European Americans and occur at low frequencies (\<0.05) in the Latino populations. However, multiple other SNPs in the *PYHIN1* region showed evidence for association only in the African American/African Caribbean sample ([Figure 1](#F1){ref-type="fig"}), whereas none showed evidence of association with asthma in Latinos or European Americans (see [Supplementary Fig. 6 online](#SD1){ref-type="supplementary-material"}), suggesting that this association may be specific to populations of African descent. In fact, rs1102000 in *PYHIN1* (also known as *IFIX*) has a relatively large effect size (OR=1.34 in the GWAS meta-analysis, OR=1.23 in the replication samples), suggesting an important role for this gene in risk for asthma in African American and African Caribbean populations.

The associations with SNPs in *PYHIN1* (pyrin and HIN domain family member 1; *IFIX*, interferon inducible nuclear protein X) with asthma are the first genome-wide significant associations reported in African Americans or African Caribbeans and may be the first asthma susceptibility gene specific to populations of African descent. The associated SNPs are in an LD bin in HapMap YRI samples, spanning \~30kb within the seventh intron of the gene, suggesting that the causal variation is contained within this intron. Imputation of additional SNPs in *PYHIN1* using pilot data from the 1000 Genomes Project yielded no additional signals of association (see [Supplementary Fig. 7 online](#SD1){ref-type="supplementary-material"}). However, the incomplete coverage of *PYHIN1* makes any conclusions on causal variation inaccurate (see [Supplementary Fig. 8 online](#SD1){ref-type="supplementary-material"}). Interestingly, the most strongly associated variants discovered in this study are not present in populations of European descent. Although, it is possible that rare variants in *PHYIN1* that are not tagged by the SNPs included in this study are risk alleles for asthma in European American and Latino populations, none of the multiple SNPs in this gene that were associated with asthma in the African American/African Caribbean populations showed evidence for association in the European Americans or Latinos. This further suggests that the African-specific variants may be causal or in LD with other African-specific causal variants in this gene. Moreover, estimates of local ancestry at *PYHIN1* in the African American/African Caribbean samples did not differ between cases and controls for any of the studies (combined p=0.77; see [Supplementary Table 6 online](#SD1){ref-type="supplementary-material"} for more details), indicating that the African-American specific association is present in the absence of an admixture signal and that the observed association is not due to uncorrected local ancestry. At present, little is known about the function of *PYHIN1*, although it is expressed in both adult leukocytes and lung tissues and the pyrin domain is a protein-protein interaction domain that is present in many interferon-inducible proteins that functions in both apoptotic and inflammatory pathways (see URL). This family of genes has been previously associated with autoimmunity^[@R24]^, but to date *PYHIN1* has not been implicated in asthma pathogenesis.

Lastly, we examined the evidence for association with SNPs that were associated with asthma in previous GWAS other than those included in the EVE meta-analysis (see [Supplementary Table 5 online](#SD1){ref-type="supplementary-material"}). These included SNPs in or near *HLA-DQ*^[@R9],[@R23]^, the 17q12 asthma locus^[@R23]^, *IL33*^[@R23]^, *IL1RL1*^[@R23]^, *SMAD3*^[@R23]^, *IL2RB*^[@R23]^, *RORA*^[@R23]^, *SLC22A5*^[@R23]^, *IL13*^[@R9],[@R23]^, *RAD50*^[@R9]^, and *DENND1B*^[@R10]^. We were able to replicate at p\<0.05 associations with SNPs at the *HLA-DQ* locus in all three ethnic groups and in the combined sample, although no single SNP was associated in all three groups. The two SNPs associated at the 17q21 asthma locus in the GABRIEL Study were also associated with asthma in our study, although one (rs2894194) showed little evidence for association in the African American/African Caribbean samples. Among the remaining SNPs associated in the GABRIEL study, we replicated associations with the same SNPs in or near the *IL18RL1*, *IL33, SLC22A5, SMAD3*, and *RORA* genes. SNPs at the latter three loci were associated only in the European American sample. Lastly, we replicated associations with two SNPs in *RAD50*, with the signals coming largely from the Latino and African American/African Caribbean samples. A SNP at the *IL2RB* locus that was associated with asthma in the GABRIEL Study was nearly significant in the European American EVE sample (p=0.06). We did not replicate associations with SNPs at the *IL13*^[@R9],[@R23]^ and *DENNDB1*^[@R10]^ loci.

The results reported here highlight the importance of studying large datasets of diverse populations in several ways. First, the large sample size allowed us to first discover and then replicate loci with modest effects. For example, SNPs at the *IL1RL1*, *TSLP*, and *IL33* loci did not reach genome-wide significance in any of the ethnic-specific meta-analyses, but SNPs in *IL1RL1* and *TSLP* reached this threshold of significance, and *IL33* approached genome-wide significance, in the overall analysis ([Table 2](#T2){ref-type="table"}; see [Supplementary Figs. 10--12 online](#SD1){ref-type="supplementary-material"}). The modest, but real, effect of variants on asthma risk likely explains why this locus was not identified as an asthma susceptibility locus in previous genome wide association studies in individual samples^[@R7]--[@R11],[@R13]^, but was among the most significant associations in the EVE and GABRIEL meta-analyses.

Second, the diverse ancestries of the EVE Consortium samples provided a more accurate and more complete picture of asthma risk by identifying common variants at four loci (17q21 locus, *IL1RL1*, *TSLP*, and *IL33*) that increase risk in all ethnic groups and at least one locus (*PYHIN1*) that may contribute to risk only in populations of African descent. Replication of previously associated variants in the EVE samples may also provide additional insights into those genes. For example, the SNPs in or near *SMAD3* and *RORA* reported in the GABRIEL Study meta-analysis were modestly associated with asthma in the European American EVE samples but showed no association in the African American/African Caribbean samples, suggesting that these may be risk variants only in populations of European descent. We anticipate that ongoing studies in the EVE Consortium data sets will identify other loci contributing to asthma risk and, ultimately provide a better understanding of the molecular pathways and networks that are common to the risk architecture of asthma in diverse populations, and those that are specific to certain groups.

Methods {#S1}
=======

GWAS subjects, genotyping and statistical analyses {#S2}
--------------------------------------------------

Asthma cases, unaffected controls, asthmacase parent trios, and extended families were recruited in clinics in the U.S, Mexico, and Barbados. Twelve samples with GWAS data were included in this study ([Table 1](#T1){ref-type="table"}). Detailed descriptions of the individual studies, ascertainment schemes, genotyping platforms, quality control (QC) protocols, and statistical analyses for the primary association testing are described in the [Supplementary Note online](#SD1){ref-type="supplementary-material"}.

Meta-analysis: QC and testing for association {#S3}
---------------------------------------------

Summary files on a common set of SNPs were shared among the EVE investigators. The common set of SNPs consisted of all Phase 2, Release 21 consensus HapMap variants. Prior to genotype imputation, each center oriented their SNPs to the plus strand, and filtered for call rates (\> 95%) and consistency with Hardy-Weinberg expectations (p \> 10^−5^ for case/control studies, p \> 10^−6^ for trio studies). Genotype imputation using HapMap reference panels were performed separately in each sample with the program MACH^[@R25]^, and associations were tested using the genotype dosages that are part of the imputation algorithms output, with adjustments for admixture in the African American and Latino case-control samples (see [Supplementary Note online](#SD1){ref-type="supplementary-material"}). The shared summary files contained the SNP identifiers (rs number, chromosome, position, alleles), SNP QC metrics (call rate, Hardy-Weinberg equilibrium p-value, imputation quality metrics), and information related to the test for association (allele frequencies in cases and controls or in the transmitted and untransmitted alleles in trios, association p-value, odds ratios with standard errors). Reference alleles were assigned as the allele coded 0 in the HapMap release 21 phased consensus haplotypes during genotype imputation in MACH. The QC checks performed on summary file data included consistency in reference allele and strand orientation (see [Supplementary Figs. 13−15 online](#SD1){ref-type="supplementary-material"}), and imputation quality (see [Supplementary Fig. 16 online](#SD1){ref-type="supplementary-material"}). SNPs with imputation quality scores below a threshold were removed from the analysis (Rsq \< 0.3 or \< 0.5 for the Barbados study). QQ plots were visually inspected to compare the distribution of association p-values for genotyped and imputed markers separately for each cohort.

The meta-analysis searched for asthma susceptibility variants for which the same allele was associated with asthma in the different studies. For each study, we constructed a test statistic that has a standard normal distribution under the null hypothesis of no association and captures the direction of the effect (i.e., the statistic was positive if the reference allele was associated with an increased risk of asthma). The meta-analysis test statistic was calculated as a linear combination of the individual study scores with weights proportional to the square root of the number of cases (or trios). P-values were obtained using normal approximations. Odds ratios were calculated by combining linearly log odds ratios with weights reflecting the standard errors from the genome-wide association studies.

Replication samples and genotyping {#S4}
----------------------------------

The replication cohorts and sample sizes are shown in [Supplementary Table 4 online](#SD1){ref-type="supplementary-material"}. Detailed descriptions of these samples, genotyping technologies, QC protocols, and statistical analyses are described in the [Supplementary Note online](#SD1){ref-type="supplementary-material"}.

Association testing in replication samples {#S5}
------------------------------------------

The combined analysis of the replication samples was performed in a similar manner to the meta-analysis. For each study, we constructed a test statistic that had standard normal distribution under the null hypothesis of no association, and that also captured the direction of the effect. A combined test statistic was calculated as a linear combination of the individual study scores with weights proportional to the square root of the number of cases, and p-values were obtained using normal approximations.

Imputation of pilot data from the 1000 Genomes Project {#S6}
------------------------------------------------------

Pilot data from the 1000 Genomes Project (August 2010 haplotypes) was used to impute a 2Mb region surrounding the *PYHIN1* gene in all studies using impute2^[@R26]^. The EUR haplotypes (European) were used as a reference for the European American studies (assuming an effective population size \[Ne\] of 11418), the EUR and AFR (African) haplotypes were used as a reference for the African American studies (assuming Ne=15000), and the EUR, AFR, and ASN (Asian haplotypes) were used as a reference for the Latino studies (assuming Ne=15000). Individual genotypes were filtered for probabilities \> 90%, and only SNPs with call rates \> 90% were included in allelic tests of association. For family-based studies, SNPs with Mendelian errors were removed.
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![Results of Meta-Analysis on the Chromosome 1 Region of Association in African Americans/African Caribbeans\
The relative location of the *PYHIN1* gene and direction of transcription are shown in the lower portion of the figure, and the chromosomal position on the x-axis. The light blue line shows the recombination rate across the region (right y-axis), and the left y-axis shows the significance of the associations. The large red diamond shows the p-value for rs1102000. The small diamonds in show the p-values for all other SNPs, color-coded according to the level of LD with rs1102000 in the HapMap YRI (red, *r*^2^ \> 0.9; orange, *r*^2^ = 0.7--0.9; yellow, *r*^2^ = 0.5--0.7). Results for the European American, Latino, and combined meta-analysis are shown in [Supplementary Fig. 6 online](#SD1){ref-type="supplementary-material"}.](nihms-304749-f0001){#F1}

###### 

Baseline characteristics of subjects in meta-analysis.

  Sample[\^](#TFN1){ref-type="table-fn"}               Genotyping Platform^[+](#TFN2){ref-type="table-fn"}^   N Asthma Cases   Sex Ratio (M:F)   AGE OF ONSET (YRS) (ASTHMA)          AGE AT ENROLLMENT (YRS)              \% Atopic[\*](#TFN5){ref-type="table-fn"}                  
  ---------------------------------------------------- ------------------------------------------------------ ---------------- ----------------- ------------------------------------ ------------------------------------ ------------------------------------------- -------------- ------
  **European Americans**                                                                                                                                                                                                                                                              
  CAG/CSGA/SARP                                        1Mv1                                                   843              321:522           13.1 (13.7)                          8.0 (3--66)                          32.0 (15.6)                                 31 (6--74)     79.3
  CARE^[@](#TFN3){ref-type="table-fn"}^                6.0                                                    217              148:69            2.1 (2.4)                            1.1 (0--12)                          6.0 (4.1)                                   3.8 (1--17)    68.1
  CAMP^[@](#TFN3){ref-type="table-fn"}^ ([@R8])        550K                                                   403              242:143           3.1 (2.5)                            2.5 (0--11)                          8.8 (2.1)                                   8.6 (5--13)    87.5
  CHS                                                  550K, 610K                                             643              348:295           7.0 (5.0)                            7.1 (0--18)                          8.4 (2.1)                                   9.0 (5--14)    NA
  **African American/African Caribbeans**                                                                                                                                                                                                                                             
  Barbados^[%](#TFN4){ref-type="table-fn"}^ ([@R13])   650K                                                   355              176:179           8.2 (10.6)                           5.0 (0--63)                          20.8 (12.9)                                 16 (3--73)     71.0
  CAG/CSGA/SARP                                        1Mv1                                                   644              266:378           9.8 (12.4)                           5.0 (0--63)                          26.4 (15.8)                                 24 (6--18)     84.2
  GRAAD ([@R13])                                       650K                                                   464              211:253           11.9 (13.2)                          7.0 (0--65)                          24.4 (17.6)                                 18 (4--76)     85.2
  SAPPHIRE                                             6.0                                                    149              60:89             10.5 (11.6)                          7.0 (0--50)                          32.3 (13.3)                                 31 (12--56)    91.3
  **Latino**                                                                                                                                                                                                                                                                          
  CARE^[@](#TFN3){ref-type="table-fn"}^                6.0                                                    52               41:11             1.4 (1.6)                            1.0 (0--8)                           4.8 (3.2)                                   3.7 (1--13)    58.8
  CHS                                                  550K, 610K                                             606              339:267           6.8 (4.8)                            7.6 (0--18)                          7.4 (1.7)                                   6.9 (5--14)    NA
  GALA^[@](#TFN3){ref-type="table-fn"}^                6.0                                                    538              302:236           5.7 (6.8)                            3.0 (0--39)                          14.8 (7.7)                                  12.0 (7--40)   79.1
  MCCAS^[@](#TFN3){ref-type="table-fn"}^([@R11])       550K                                                   492              289:283           ^[\#](#TFN6){ref-type="table-fn"}^   ^[\#](#TFN6){ref-type="table-fn"}^   9.0 (2.4)                                   9 (5--17)      92.0

There were a total of 3246 cases, 3385 controls, 1702 case-parent trios, and 355 family-based cases and 468 family-based controls included in the meta-analysis. Unless otherwise indicated samples are unrelated asthma cases and non-asthma controls. Descriptions of the individual study samples are in the [Supplementary Methods online](#SD1){ref-type="supplementary-material"}. References for published GWAS in the individual samples are shown in the first column. NA, information not available.

CARE, Clinical Asthma Research Network; CAMP, Childhood Asthma Management Program; CHS, Children\'s Health Study; CAG, Chicago Asthma Genetics Study; CSGA, Collaborative Studies on the Genetics of Asthma; SARP, Severe Asthma Research Program; GRAAD, Genetic Research on Asthma in the African Diaspora; SAPPHIRE, Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity; GALA, Genetics of Asthma in Latino Americans; MCCAS, Mexico City Childhood Asthma Study

Illumina arrays: 1Mv1, 550k, 610k, 650k; Affymetrix arrays: 500k, 6.0

Asthma case-parent trios

Family-based cases and controls

1 or more positive allergen skin test or specific IgE, or high total IgE

Age of onset was queried as a categorical varaiable. Percentages in each category were: \<1 yr=7.1%, 2--3 yrs=25.6%, 4--5 yrs=29.1%, 6--7 yrs=17.7%, 8--9 yrs=11.6%, \>9=8.9%.

###### 

Results of meta-analyses.

                                               P-value   OR (95% CI)                                                                                                                                            
  -------------------------------------------- --------- ------------- ----- ---- ------------ ------------ ------------ ------------ ------------- ------------------- ------------------- ------------------- -------------------
  rs4845783                                    1         150,759,183   G/A   3    *CRCT1*      0.0023       2.3×10^−4^   0.048        5.6×10^−7^    1.18 (1.04, 1.33)   1.35 (1.02, 2.04)   1.09 (0.94, 1.30)   1.16 (1.06, 1.28)
  rs1102000                                    1         155,745,980   T/C   2    *PYHIN1*     NA           3.6×10^−7^   0.12         3.6×10^−6^    NA                  1.34 (1.19, 1.49)   1.04 (0.47, 1.62)   1.32 (1.17, 1.46)
  rs4653433                                    1         224,041,154   A/G   1    *SRP9*       0.0026       .027         6.2×10^−4^   5.4×10^−7^    1.13 (1.03, 1.23)   1.12 (0.99, 1.24)   1.16 (1.04, 1.29)   1.14 (1.07, 1.2)
  rs10173081[\*](#TFN7){ref-type="table-fn"}   2         102,323,780   C/T   13   *IL1RL1*     1.3×10^−4^   0.07         4.5×10^−5^   1.4×10^−8^    1.28 (1.13, 1.42)   1.1 (0.96, 1.23)    1.28 (1.08, 1.48)   1.2 (1.11, 1.29)
  rs2017908^[+](#TFN8){ref-type="table-fn"}^   3         188,900,662   A/C   13   *RTP2*       0.24         0.67         4.4×10^−9^   0.0049        0.93 (0.79, 1.08)   1.03 (0.9, 1.17)    1.63 (1.43, 1.82)   1.09 (1, 1.18)
  rs11735820                                   4         66,181,611    G/T   2    *EPHA5*      1.5×10^−4^   0.003        0.033        2.3×10^−7^    1.18 (1.08, 1.28)   1.15 (1.02, 1.27)   1.14 (1, 1.28)      1.16 (1.09, 1.23)
  rs1837253[\*](#TFN7){ref-type="table-fn"}    5         110,429,771   C/T   1    *TSLP*       1.1×10^−5^   0.0023       0.0018       7.3×10^−10^   1.23 (1.12, 1.35)   1.2 (1.06, 1.35)    1.14 (1.01, 1.27)   1.19 (1.12, 1.27)
  rs10064618                                   5         153,752,482   G/A   1    *GALNT10*    0.76         0.36         5.7×10^−7^   4.4×10^−4^    1.01 (0.93, 1.12)   1.08 (0.93, 1.28)   1.25 (1.09, 1.47)   1.10 (1.02, 1.19)
  rs2453626                                    8         101,207,073   C/T   1    *FBXO43*     0.0044       2.1×10^−4^   0.016        2.8×10^−7^    1.15 (1.05, 1.24)   1.24 (1.11, 1.37)   1.13 (1, 1.26)      1.17 (1.1, 1.23)
  rs2381416                                    9         6,183,455     C/A   2    *IL33*       0.011        0.0022       6.6×10^−4^   2.5×10^−7^    1.18 (1.04, 1.35)   1.14 (0.99, 1.32)   1.22 (1.04, 1.47)   1.18 (1.08, 1.28)
  rs11214966                                   11        113,736,465   C/T   2    *C11orf71*   0.76         3.5×10^−7^   0.59         0.0012        1.02 (0.83, 1.21)   1.35 (1.2, 1.51)    1.04 (0.86, 1.22)   1.16 (1.06, 1.26)
  rs16929496                                   12        25,885,071    T/C   3    *RASSF8*     3.2×10^−4^   0.025        0.0027       2.6×10^−7^    1.23 (1.06, 1.45)   1.10 (0.94, 1.33)   1.25 (1.02, 1.61)   1.19 (1.08, 1.33)
  rs9891949                                    17        8,039,908     A/G   1    *AURKB*      7.5×10^−7^   0.68         0.73         4.5×10^−4^    1.25 (1.15, 1.36)   1.06 (0.94, 1.18)   1.02 (0.89, 1.14)   1.12 (1.05, 1.19)
  rs11078927[\*](#TFN7){ref-type="table-fn"}   17        35,317,931    C/T   49   *GSDMB*      8.6×10^−7^   0.0012       3.1×10^−7^   1.2×10^−14^   1.25 (1.15, 1.35)   1.31 (1.13, 1.5)    1.29 (1.16, 1.42)   1.27 (1.2, 1.34)
  rs335016                                     19        35,065,232    A/C   2    *C19orf2*    0.16         0.68         2.6×10^−7^   5.8×10^−5^    1.05 (0.94, 1.16)   1 (0.86, 1.14)      1.25 (1.12, 1.38)   1.09 (1.02, 1.17)

The most significant SNP in each region with at least one p-value \<1×10^−6^ in the combined sample or in at least one ancestry group, sorted by chromosome. Results for all SNPs with p-values \<1×10^−6^ are shown in [Supplementary Table 4 online](#SD1){ref-type="supplementary-material"} (p-values) and [Supplementary Table 5 online](#SD1){ref-type="supplementary-material"} (minor allele frequencies and imputation quality scores). \#SNPS, number of SNPs in a 1 Mb region with p-values \<1×10^−6^. NA, not available (SNP not polymorphic);

genome-wide significant in the combined sample

genome-wide significant in Latinos only.

###### 

Replication study results.

  SNP                           Chr   Position      Nearest Gene   Replication Meta-analysis P-values   Meta-analysis + Replication P-values                              
  ----------------------------- ----- ------------- -------------- ------------------------------------ -------------------------------------- ------------ ------------- --------------------------------------------
  Replicated Associations                                                                                                                                                 
  rs1101999                     1     157,199,179   *PYHIN1*       NA                                   0.0028                                 0.28         0.64          3.9×10^−9^[\^](#TFN9){ref-type="table-fn"}
  rs3771180                     2     102,323,780   *IL1RL1*       0.17                                 0.0018                                 2.5×10^−5^   5.3×10^−7^    1.5×10^−15^
  rs1837253                     5     110,429,771   *TSLP*         0.0076                               0.012                                  0.0010       1.59×10^−6^   1.0×10^−14^
  rs2381416                     9     6,183,455     *IL33*         0.0026                               0.010                                  0.0034       1.3×10^−6^    1.7×10^−12^
  rs11078927                    17    35,317,931    *GSDMB*        7.4×10^−7^                           0.86                                   4.1×10^−7^   1.5×10^−8^    2.2×10^−16^
  Non-replicated Associations                                                                                                                                             
  rs4845783                     1     150,759,183   *CRCT1*        0.25                                 0.74                                   0.24         0.15          6.2×10^−6^
  rs2017908                     3     188,900,662   *RTP2*         0.25                                 0.56                                   0.24         0.88          0.0030^[+](#TFN10){ref-type="table-fn"}^
  rs11735820                    4     66,181,611    *EPHA5*        0.29                                 0.37                                   0.52         0.15          0.010
  rs10064618                    5     153,752,482   *GALNT10*      0.30                                 0.69                                   0.52         0.32          1.7×10^−4[+](#TFN10){ref-type="table-fn"}^
  rs2453626                     8     101,207,073   *FBXO43*       0.71                                 0.66                                   0.06         0.28          0.0049
  rs11214966                    11    113,736,465   *C11orf71*     0.72                                 0.18                                   0.15         0.48          6.3×10^−7^[\^](#TFN9){ref-type="table-fn"}
  rs16929496                    12    25,885,071    *RASSF8*       0.44                                 0.59                                   0.28         0.97          3.7×10^−4^
  rs335016                      19    35,065,232    *C19orf2*      0.83                                 0.88                                   0.75         1.00          0.0018^[+](#TFN10){ref-type="table-fn"}^

SNP rs1101999 in *PYHIN1* is in perfect LD with rs1102000 (Table 2) in African Americans (*r*^2^=1.0), and was used as a surrogate SNP in the replication studies (neither SNP is polymorphic in European Americans); rs3771180 used as a surrogate SNP for rs10173081 near *IL1RL1*. Two associated SNPs could not be assayed in the replication samples: rs4653433 near *SRP9* and rs9891949 near *AURKB*. NA, not available.

P-value is combined for only the African American and African Caribbean populations

P-value is combined for only the Latino populations
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